This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cummings, D. E. Articles by Bremner, W. J. Search for Related Content PubMed PubMed Citation Articles by Cummings, D. E. Articles by Bremner, W. J.

Prostate-Sparing Effects in Primates of the Potent Androgen 7-Methyl-19-Nortestosterone: A Potential Alternative to Testosterone for Androgen Replacement and Male Contraception¹

University of Washington School of Medicine (D.E.C., W.J.B.); Population Center for Research in Reproduction; and the Department of Medicine, Division of Endocrinology and Metabolism, Veterans Affairs, Puget Sound Health Care System, Seattle, Washington 98108; and the Center for Biomedical Research, The Population Council (N.K., C.W.B., K.S.), New York, New York 10021

Address all correspondence and requests for reprints to: William J. Bremner, M.D., Ph.D., University of Washington School of Medicine, Population Center for Research in Reproduction, Department of Medicine, Division of Endocrinology and Metabolism, Seattle Veterans Administration Medical Center, 1660 South Columbian Way, Seattle, Washington 98108. E-mail: bremner{at}seattle.va.gov

7-Methyl-19-nortestosterone (MENT) is a potent synthetic androgen that cannot be converted to dihydrotestosterone. In this study we determined the relative androgenic, antigonadotropic, and anabolic potencies of testosterone vs. MENT in the nonhuman primate M. fascicularis. In castrated monkeys, dose-response relationships were generated for the effects of testosterone and MENT on gonadotropin levels, prostate growth, body weight, and lipid metabolism. In a pilot study, four monkeys were castrated, and magnetic resonance imaging (MRI) was used to document a 50% loss of prostate volume within 8 weeks, verifying that MRI is a reliable means to measure prostate size in this species. Two additional groups of six monkeys each were then castrated and serially administered four graded dosages of testosterone or MENT via osmotic minipumps over 20 weeks. Complete suppression of LH was achieved with a minimum of 0.3 mg/day MENT, compared to 3.0 mg/day testosterone. MENT supported body weight 10 times more potently than did testosterone. Baseline prostate volumes were maintained with 0.1–0.2 mg/day MENT vs. 0.3 mg/day testosterone. Thus, in monkeys, MENT is 10 times more potent than testosterone with regard to the clinically desirable end points of gonadotropin suppression and anabolism, but only twice as potent at stimulating prostate growth. These results suggest that MENT may have a wider therapeutic index than testosterone for human androgen replacement and male contraception.

This article has been cited by other articles:

				M. J. Walton, N. Kumar, D. T. Baird, H. Ludlow, and R. A. Anderson 7{alpha}-Methyl-19-Nortestosterone (MENT) vs Testosterone in Combination With Etonogestrel Implants for Spermatogenic Suppression in Healthy Men J Androl, September 1, 2007; 28(5): 679 - 688. [Abstract] [Full Text] [PDF]

				K. L. Matthiesson and R. I. McLachlan Male hormonal contraception: concept proven, product in sight? Hum. Reprod. Update, July 1, 2006; 12(4): 463 - 482. [Abstract] [Full Text] [PDF]

				B. J. Attardi, S. A. Hild, and J. R. Reel Dimethandrolone Undecanoate: A New Potent Orally Active Androgen with Progestational Activity Endocrinology, June 1, 2006; 147(6): 3016 - 3026. [Abstract] [Full Text] [PDF]

				J. M. Kaufman and A. Vermeulen The Decline of Androgen Levels in Elderly Men and Its Clinical and Therapeutic Implications Endocr. Rev., October 1, 2005; 26(6): 833 - 876. [Abstract] [Full Text] [PDF]

				J. Chen, J. Kim, and J. T. Dalton Discovery and Therapeutic Promise of Selective Androgen Receptor Modulators Mol. Interv., June 1, 2005; 5(3): 173 - 188. [Abstract] [Full Text] [PDF]

				S. von Eckardstein, G. Noe, V. Brache, E. Nieschlag, H. Croxatto, F. Alvarez, A. Moo-Young, I. Sivin, N. Kumar, M. Small, et al. A Clinical Trial of 7{alpha}-Methyl-19-Nortestosterone Implants for Possible Use as a Long-Acting Contraceptive for Men J. Clin. Endocrinol. Metab., November 1, 2003; 88(11): 5232 - 5239. [Abstract] [Full Text] [PDF]

				B. A. L. Crawford, P. Y. Liu, M. T. Kean, J. F. Bleasel, and D. J. Handelsman Randomized Placebo-Controlled Trial of Androgen Effects on Muscle and Bone in Men Requiring Long-Term Systemic Glucocorticoid Treatment J. Clin. Endocrinol. Metab., July 1, 2003; 88(7): 3167 - 3176. [Abstract] [Full Text] [PDF]

				R. A. Anderson, A. M. Wallace, N. Sattar, N. Kumar, and K. Sundaram Evidence for Tissue Selectivity of the Synthetic Androgen 7{alpha}-Methyl-19-Nortestosterone in Hypogonadal Men J. Clin. Endocrinol. Metab., June 1, 2003; 88(6): 2784 - 2793. [Abstract] [Full Text] [PDF]

				E. C. Raney and J. Methot Recent Advances in Hormonal and Barrier Contraception Journal of Pharmacy Practice, June 1, 2003; 16(3): 209 - 217. [Abstract] [PDF]

				R. A. Anderson and D. T. Baird Male Contraception Endocr. Rev., December 1, 2002; 23(6): 735 - 762. [Abstract] [Full Text] [PDF]

				A. Narula, Y.-Q. Gu, L. O'Donnell, P. G. Stanton, D. M. Robertson, R. I. McLachlan, and W. J. Bremner Variability in Sperm Suppression during Testosterone Administration to Adult Monkeys Is Related to Follicle Stimulating Hormone Suppression and Not to Intratesticular Androgens J. Clin. Endocrinol. Metab., July 1, 2002; 87(7): 3399 - 3406. [Abstract] [Full Text] [PDF]

				C. Wang and R. S. Swerdloff Should the Nonaromatizable Androgen Dihydrotestosterone Be Considered as an Alternative to Testosterone in the Treatment of the Andropause? J. Clin. Endocrinol. Metab., April 1, 2002; 87(4): 1462 - 1466. [Full Text] [PDF]

				A. M. Matsumoto Andropause: Clinical Implications of the Decline in Serum Testosterone Levels With Aging in Men J. Gerontol. A Biol. Sci. Med. Sci., February 1, 2002; 57(2): M76 - 99. [Full Text]

				H.M. Behre, S. Kliesch, B. Lemcke, S. von Eckardstein, and E. Nieschlag Suppression of spermatogenesis to azoospermia by combined administration of GnRH antagonist and 19-nortestosterone cannot be maintained by this non-aromatizable androgen alone Hum. Reprod., December 1, 2001; 16(12): 2570 - 2577. [Abstract] [Full Text] [PDF]

				R. A. Anderson, C. W. Martin, A. W. C. Kung, D. Everington, T. C. Pun, K. C. B. Tan, J. Bancroft, K. Sundaram, A. J. Moo-Young, and D. T. Baird 7{alpha}-Methyl-19-Nortestosterone Maintains Sexual Behavior and Mood in Hypogonadal Men J. Clin. Endocrinol. Metab., October 1, 1999; 84(10): 3556 - 3562. [Abstract] [Full Text] [PDF]